SynAct Pharma AB (FRA:8F8)

Germany flag Germany · Delayed Price · Currency is EUR
1.600
+0.008 (0.50%)
At close: Mar 27, 2026
Market Cap92.35M +34.5%
Revenue (ttm)n/a
Net Income-10.24M
EPS-0.20
Shares Outn/a
PE Ration/a
Forward PE17.63
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open1.562
Previous Close1.592
Day's Range1.548 - 1.600
52-Week Range1.220 - 2.320
Betan/a
RSI40.46
Earnings DateApr 15, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 8
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8F8

Financial Performance

Financial numbers in SEK Financial Statements